563 related articles for article (PubMed ID: 30605011)
21. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
[TBL] [Abstract][Full Text] [Related]
22. Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance.
Lasalle M; Hoguet V; Hennuyer N; Leroux F; Piveteau C; Belloy L; Lestavel S; Vallez E; Dorchies E; Duplan I; Sevin E; Culot M; Gosselet F; Boulahjar R; Herledan A; Staels B; Deprez B; Tailleux A; Charton J
J Med Chem; 2017 May; 60(10):4185-4211. PubMed ID: 28414465
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological activation of TGR5 promotes intestinal growth via a GLP-2-dependent pathway in mice.
Hunt JE; Billeschou A; Windeløv JA; Hartmann B; Ullmer C; Holst JJ; Kissow H
Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G980-G987. PubMed ID: 32308039
[TBL] [Abstract][Full Text] [Related]
24. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
[TBL] [Abstract][Full Text] [Related]
25. Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model.
Fang X; Du Z; Duan C; Zhan S; Wang T; Zhu M; Shi J; Meng J; Zhang X; Yang M; Zuo Y
Life Sci; 2021 Apr; 270():118966. PubMed ID: 33482185
[TBL] [Abstract][Full Text] [Related]
26. Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression.
Lee M; Shin E; Bae J; Cho Y; Lee JY; Lee YH; Lee BW; Kang ES; Cha BS
Sci Rep; 2020 Nov; 10(1):19429. PubMed ID: 33173107
[TBL] [Abstract][Full Text] [Related]
27. Metabolic phenotype and adipose and liver features in a high-fat Western diet-induced mouse model of obesity-linked NAFLD.
Luo Y; Burrington CM; Graff EC; Zhang J; Judd RL; Suksaranjit P; Kaewpoowat Q; Davenport SK; O'Neill AM; Greene MW
Am J Physiol Endocrinol Metab; 2016 Mar; 310(6):E418-39. PubMed ID: 26670487
[TBL] [Abstract][Full Text] [Related]
28. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.
Liu Y; Wei R; Hong TP
World J Gastroenterol; 2014 Jul; 20(27):9090-7. PubMed ID: 25083081
[TBL] [Abstract][Full Text] [Related]
29. Nicotinic acetylcholine receptor α7 subunit improves energy homeostasis and inhibits inflammation in nonalcoholic fatty liver disease.
Li DJ; Liu J; Hua X; Fu H; Huang F; Fei YB; Lu WJ; Shen FM; Wang P
Metabolism; 2018 Feb; 79():52-63. PubMed ID: 29129819
[TBL] [Abstract][Full Text] [Related]
30. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
[TBL] [Abstract][Full Text] [Related]
31. Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db/db mice.
Yang T; Yang H; Heng C; Wang H; Chen S; Hu Y; Jiang Z; Yu Q; Wang Z; Qian S; Wang J; Wang T; Du L; Lu Q; Yin X
Food Funct; 2020 Dec; 11(12):10675-10689. PubMed ID: 33216087
[TBL] [Abstract][Full Text] [Related]
32. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease.
Bernsmeier C; Meyer-Gerspach AC; Blaser LS; Jeker L; Steinert RE; Heim MH; Beglinger C
PLoS One; 2014; 9(1):e87488. PubMed ID: 24489924
[TBL] [Abstract][Full Text] [Related]
33. A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice.
Valdecantos MP; Pardo V; Ruiz L; Castro-Sánchez L; Lanzón B; Fernández-Millán E; García-Monzón C; Arroba AI; González-Rodríguez Á; Escrivá F; Álvarez C; Rupérez FJ; Barbas C; Konkar A; Naylor J; Hornigold D; Santos AD; Bednarek M; Grimsby J; Rondinone CM; Valverde ÁM
Hepatology; 2017 Mar; 65(3):950-968. PubMed ID: 27880981
[TBL] [Abstract][Full Text] [Related]
34. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
[TBL] [Abstract][Full Text] [Related]
35. Differential action of TGR5 agonists on GLP-2 secretion and promotion of intestinal adaptation in a piglet short bowel model.
Lin S; Stoll B; Robinson J; Pastor JJ; Marini JC; Ipharraguerre IR; Hartmann B; Holst JJ; Cruz S; Lau P; Olutoye O; Fang Z; Burrin DG
Am J Physiol Gastrointest Liver Physiol; 2019 May; 316(5):G641-G652. PubMed ID: 30920308
[TBL] [Abstract][Full Text] [Related]
36. Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates nonalcoholic fatty liver disease.
Patel V; Joharapurkar A; Kshirsagar S; Patel M; Sutariya B; Patel H; Pandey D; Patel D; Ranvir R; Kadam S; Bahekar R; Jain M
Can J Physiol Pharmacol; 2018 Jun; 96(6):587-596. PubMed ID: 29406832
[TBL] [Abstract][Full Text] [Related]
37. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
[TBL] [Abstract][Full Text] [Related]
38. Newly identified peptide hormone inhibits intestinal fat absorption and improves NAFLD through its receptor GPRC6A.
Teng B; Huang C; Cheng CL; Udduttula A; Yu XF; Liu C; Li J; Yao ZY; Long J; Miao LF; Zou C; Chu J; Zhang JV; Ren PG
J Hepatol; 2020 Aug; 73(2):383-393. PubMed ID: 32147363
[TBL] [Abstract][Full Text] [Related]
39. Role of Bile Acids and GLP-1 in Mediating the Metabolic Improvements of Bariatric Surgery.
Albaugh VL; Banan B; Antoun J; Xiong Y; Guo Y; Ping J; Alikhan M; Clements BA; Abumrad NN; Flynn CR
Gastroenterology; 2019 Mar; 156(4):1041-1051.e4. PubMed ID: 30445014
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of novel TGR5 agonist in combination with Sitagliptin for possible treatment of type 2 diabetes.
Agarwal S; Sasane S; Kumar J; Deshmukh P; Bhayani H; Giri P; Giri S; Soman S; Kulkarni N; Jain M
Bioorg Med Chem Lett; 2018 Jun; 28(10):1849-1852. PubMed ID: 29655980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
